In September 2025, the FDA issued over 50 warning letters to companies marketing compounded GLP-1 products with misleading claims
Missing doses or inconsistent timing can result in suboptimal glucose control and reduced therapeutic benefit
The message would still need to be for pregnant women and those planning pregnancy to follow the label and their clinicians advice regarding GLP-1 when pregnant or planning pregnancy, she said
What they are, how they work, and what medications are FDA-approved today In recent years, weight loss medications, especially GLP-1 receptor agonists , have gained popularity
Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells